Principal Financial Group Inc Day One Biopharmaceuticals, Inc. Transaction History

Principal Financial Group Inc

  • $172 Billion
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024
BUY
$13.56 - $17.46 $1,464 - $1,885
108 Added 0.6%
17,977 $296,000
Q4 2023

Feb 07, 2024
BUY
$9.68 - $15.37 $851 - $1,352
88 Added 0.49%
17,869 $260,000
Q3 2023

Nov 02, 2023
BUY
$11.22 - $14.86 $17,604 - $23,315
1,569 Added 9.68%
17,781 $218,000
Q2 2023

Aug 07, 2023
BUY
$11.74 - $14.47 $29,338 - $36,160
2,499 Added 18.22%
16,212 $193,000
Q1 2023

May 09, 2023
BUY
$12.75 - $23.41 $8,733 - $16,035
685 Added 5.26%
13,713 $183,000
Q4 2022

Feb 09, 2023
BUY
$18.77 - $22.0 $244,535 - $286,616
13,028 New
13,028 $280,000

Others Institutions Holding DAWN

# of Institutions
178
Shares Held
84M
Call Options Held
144K
Put Options Held
218K
View Full List

About Day One Biopharmaceuticals, Inc.

DAWN Quotes by TradingView
  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $1.01B
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email